Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/48—Reproductive organs
  • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/48—Reproductive organs
  • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Definitions

• MSC mesenchymal stem cells
• progenitor cells for example muscle progenitor cells, connective tissue cell progenitors or oval cells. Muscle progenitor cells differentiate further into cardiac, skeletal as well as smooth muscle cells whereas the connective tissue cell progenitor may differentiate into bone.
• USSCs unrestricted somatic stem cells
• USSCs can be derived from human umbilical cord blood, placental blood and/or the blood from a newborn child.
• USSCs are distinct from but capable to differentiate into mesenchymal stem or progenitor cells, hematopoietic lineage stem or progenitor cells, neural stem or progenitor cells, or endothelial stem or liver progenitor cells.
• USSCs represent the progenitor of the hematopoietic lineage, the mesenchymal stem cells as well as neural stem cells.
• USSCs suspended in a pharmaceutically acceptable buffer are administered to the patient intravenously as soon as possible, and preferably within 24 hours, after onset of the myocardial infarction.
• Other appropriate treatment regimens are employed at the same time.
• the blood flow to the heart is evaluated after two weeks; this involves standard oxygenation tests, and can also involve angiography, which can determine that the USSCs have brought about increased collateral blood vessel supply to the heart. If desired, additional USSCs can be administered at this time to further increase collateral circulation.
• USSCs can be isolated and purified by the steps of density gradient isolation, culture of adherent cells, and subculture applying growth factors as described below.
• Hyaluronan Synthase gene D84424
• Fibromodulin gene UO 5291
• the transcript INFLS W03846
• Northern blot analysis indicated that Hyaluronan Synthase is ubiquitously expressed in human tissues (Itano and Kimata, 1996).
• the product of this enzyme, Hyaluronan serves a variety of functions, including space filling, lubrication of joints, and provision of a matrix through which cells can migrate (Hall et al., 1995).
• Fibromodulin is a member of a family of small interstitial proteoglycans. The protein exhibits a wide tissue distribution, with the highest abundance observed in articular cartilage, tendon, and ligament (Sztrolovics et al., 1994).
• the transcript INFLS was cloned from human fetal liver.
• the USSCs may be desirable to administer the USSCs locally to the area in need of treatment for ischemic damage, or the risk thereof; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, by injection, by means of a catheter, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
• the USSCs can be delivered in a vesicle, in particular a liposome (e.g., an encapsulated liposome).
• Another possible administration route for USSCs is via direct surgical injection (e.g., intramyocardial or transendocardial injection, intracranial, intracerebral, or intracisternal injection, intramuscular injection, intrahepatic injection, and intrapancreatic injection) into the tissue or region of the body to be treated (e.g., the brain, muscle, heart, liver, pancreas, and vasculature).
• This method of administration may also require multiple injections with treatment interruption intervals lasting from 2 weeks to 6 months, or as otherwise determined by the attending physician.
• All three marker genes of osteogenic differentiation show an increased mRNA expression at day 7 of DAG induction.
• B-actin serves as a positive control.
• CB-derived MNCs were plated at a density of 5x10 6 /ml in 10 ml Myelocult H5100 Medium (StemCell Technologies, Vancouver, Canada) into 50 ml culture- flasks (Nunclon) without dexamethasone.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Cell Biology (AREA)
• Developmental Biology & Embryology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Virology (AREA)
• Reproductive Health (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Hematology (AREA)
• Heart & Thoracic Surgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pregnancy & Childbirth (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cardiology (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=37482164

Family Applications (1)

Country Status (4)

Cited By (2)

Families Citing this family (16)

Family Cites Families (20)

• 2006
  • 2006-05-26 WO PCT/US2006/020290 patent/WO2006130433A2/en not_active Ceased
  • 2006-05-26 EP EP13001977.1A patent/EP2662439A1/en not_active Withdrawn
  • 2006-05-26 EP EP06771203.4A patent/EP1888741B1/en not_active Revoked
  • 2006-05-26 JP JP2008513716A patent/JP2008545703A/ja active Pending
  • 2006-05-26 US US11/915,660 patent/US8613906B2/en active Active
• 2013
  • 2013-11-19 US US14/084,002 patent/US20140079673A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events